KBLI 21022 is open only to 100% Indonesian-owned capital under Pres. Reg. 10/2021. PT PMA cannot register under this code.
OSS RBA classifies KBLI 21022 as High — NIB + Operating Licence (Izin) at Large scale. 25 PB UMKU sector-specific permits apply depending on the exact activity. Licensing instruments follow the standard ladder; no sector-regulator override is on file for this code.
Operating this code requires Indonesian-credentialed practitioners on staff (STPT / STR / SIPA / Penanggung Jawab Teknis depending on sub-activity). PT PMA can hold the corporate licence but cannot operate without Indonesian-citizen credential holders. Most foreign investors recruit Indonesian PJs on payroll, partner with existing operators, or pivot to an adjacent KBLI.
Worth confirming: BUPM restricts foreign capital for this activity. Even where a limited path exists (local partnership, SME structuring, alternative KBLI), sector regulators may add their own requirements on top. Talk to our team
Traditional Medicine Products for Humans
Last updated · Sourced from OSS Indonesia
This group includes businesses that process various traditional medicine products made from plant materials, animal materials, mineral materials, galenic preparations, or mixtures of these materials in the form of powders, slices, pills, dodol/jenang, pastilles, tablets, capsules, liquids, solutions, emulsions and suspensions, ointments, creams and gels, and suppositories. It also includes the beverage industry for jamu and health/food supplements that are not pharmaceutical products.
Indonesia's BUPM (Investment Business Fields) regulation places this code into one of five tracks. The track determines whether a foreign investor (PMA) can operate in this activity at all, and under what conditions.
KBLI 21022 is restricted to 100% domestic ownership. Foreign investors cannot hold shares in entities operating under this code. This restriction commonly applies to traditional industries, broadcasting, and culturally significant activities.
Foreign-investor tax benefits available for this KBLI under PMK 130/2020 (Tax Holiday) and PP 78/2019 (Tax Allowance). Both require approval — see the linked guide for the application path.
Note. Pharmaceutical manufacturing (KBLI 21xxx) is on the PP 78/2019 Tax Allowance priority list.
Sector context that applies to KBLI 21022 beyond the generic OSS process. Verify with the relevant ministry before committing capital.
Current status, what each regulation actually requires for this activity, and how it ties to the PB UMKU sector permits below. Click through for the plain-English summary.
Archetypal businesses operating under this code. Use these to recognize whether your venture maps to KBLI 21022 as primary or secondary activity.
Real-world business archetypes — names omitted; profiles describe operational shape, not specific companies.
Multinational pharma operating Indonesian production facilities for ASEAN-distributed generic drugs.
An honest read of the situation, plus the structures that work in practice. We've handled all of these — book a call to walk through your specific plan.
This KBLI is reserved to 100% Indonesian capital under Pres. Reg. 10/2021. Foreign investors cannot own shares in an entity registered for this code. The honest paths forward are: (1) operate a different but related KBLI that's open to PMA, (2) partner with a fully Indonesian-owned licensee under a commercial / IP / supply agreement (not equity), or (3) explore a Special Economic Zone where the rule may be relaxed.
The cleanest path: operate a related but open KBLI. For example, foreign investors blocked from primary commodity production frequently succeed with the processing, distribution, branding, or export-trade codes upstream or downstream of the restricted activity.
Several restricted codes have higher or full PMA caps inside designated KEK zones (Sanur Health, Lido, Mandalika) or the Batam Free Trade Zone — manufacturing, logistics, and IT services especially. The IUK regime under BP Batam relaxes ownership rules selectively in exchange for export orientation. We assess whether your operation can benefit. See the for the requirements.
A 100% Indonesian-owned operating entity can hold the restricted licence while you contract with it commercially. We structure these arrangements deliberately — without nominee shareholding, which is unenforceable and increasingly scrutinised.
These siblings are usable by a foreign-owned PT PMA — they have a Large-scale licensing matrix and aren't on a restricted list. Each has its own context badge so you can pick by trade-off.
The data below is the official OSS regulatory profile for this code. It applies to qualifying Indonesian operators (or to your operating partner). Foreign investors won't file these directly, but it's useful context when structuring a partnership or commercial arrangement.
Foreign investors:the licensing matrix below is for context only — direct PMA registration isn't possible for this code. See pathways above for what actually works.
Documents and capabilities you must demonstrate at registration
Compliance and reporting duties throughout operation
The authority that issues the license depends on your situation.
| Authority | Applies when |
|---|---|
| Minister/Head of Agency | The industrial location is situated within a cross-border area between provinces. |
| Minister/Head of Agency | Foreign Investment |
| Governor | The industrial location is in the relevant province. |
PB UMKU permits sit on top of the main NIB and Sertifikat Standar — each is issued by a different ministry, and only when a specific operational activity is performed. This KBLI carries 25 candidate permits across 2 regulators; most operations only need a handful. Emerhub maps your operation to the exact set, files them, and tracks renewals.
BPOM (National Agency of Drug & Food Control). Applies to drugs, processed food, traditional medicine, cosmetics, and health supplements — produced, imported, repackaged, or distributed for human consumption. BPOM is the gating regulator; product registration is required before any commercial sale.
Ministry of Agriculture. Applies if you produce, import, distribute, or sell animal medicines, vaccines, or feed; if you breed livestock; or if you operate a veterinary practice. A "veterinary control number" (NKV) is the entry-point permit for animal-product processors.

Class-level prerequisites that apply to every operator under this KBLI, independent of business scale. These commonly include minimum capital rules for PMA entities and spatial-planning (KKPR) conformance.
Originator-brand pharma with local manufacturing of selected SKUs — common for products subject to JKN inclusion requirements.
Biologics and vaccine production facilities, often in partnership with state-owned Bio Farma — strategic-sector positioning.
Pharmaceutical manufacturing is open to PMA but tightly regulated by BPOM. Eligible for Tax Holiday under PMK 130/2020 (pharmaceutical raw materials = pioneer industry). CPOB (GMP) certification mandatory; investment commitments typically IDR 100bn+.
A plain-English explanation of this classification and the businesses it covers.
KBLI 21022 (Traditional Medicine Products for Humans) is the 5-digit Indonesian Standard Industrial Classification code for traditional medicine product industry for humans. It sits within Manufacturing Industry under the subgroup Traditional Medicine Industry (major group 21) in the official KBLI 2020 taxonomy maintained by Statistics Indonesia (BPS).
Any Indonesian or foreign-owned entity that intends to operate in traditional medicine product industry for humans as a primary or secondary business activity must select this code on its NIB (Business Identification Number). The selected code determines the licensing instruments required, the issuing authority, and the ongoing compliance obligations.
Indonesia's OSS Risk-Based Approach uses the KBLI code to determine three things: (1) whether foreign investment is permitted and at what cap, (2) the risk-based licensing instruments required, and (3) the authority that issues each instrument. Choosing the wrong code can delay or invalidate your license.
Indonesia's BPS published the new KBLI 2025 taxonomy in early 2025. OSS, BKPM and the operating ministries have not yet adopted it — KBLI 2020 remains the active standard for business registration. This is what's coming for this specific code.
KBLI 21022 retains the same code number and scope in the new taxonomy. The activity description, hierarchy, and intended use of the code are preserved.
When OSS adopts KBLI 2025, we'll migrate your existing entity to the appropriate successor code as part of ongoing compliance — no action needed on your end now.
Talk to a specialistIndonesia's OSS Risk-Based Approach assigns a separate risk level for each of the four business scales. The licensing instruments required (NIB, Standard Certificate, Operating License) are determined by the risk level. Foreign-owned entities (PT PMA) must register at the Large scale, so the rightmost column applies to most foreign investors.
KBLI 21022 (Traditional Medicine Products for Humans) is the 5-digit Indonesian Standard Industrial Classification code for traditional medicine product industry for humans. It sits within the Manufacturing Industry category in the official KBLI 2020 taxonomy maintained by Badan Pusat Statistik (BPS).
No — KBLI 21022 is reserved for 100% Indonesian capital under Pres. Reg. 10/2021. Foreign investors cannot hold shares in entities operating under this code. Common in traditional industries, broadcasting, and culturally significant activities.
KBLI 21022's risk levels per business scale: Micro High, Small High, Medium High, Large High. Foreign-owned entities (PT PMA) must register at the Large scale.
Not applicable to PT PMA — KBLI 21022 is not viable for foreign-owned entities, so neither BKPM Reg. 5/2025's paid-up minimum nor any sector-specific capital floor enters the picture. The structural barrier comes first.
Not applicable to PT PMA — KBLI 21022 is not viable for foreign-owned entities, so the 4-8 week PT PMA setup timeline doesn't apply. Move to a sibling code with a Large-scale matrix or a different structure.
Yes — KBLI 21022 is on the Tax Allowance priority list (PP 78/2019). Eligible for 30% reduction of taxable net income over 6 years plus accelerated depreciation.
Not applicable to PT PMA — KBLI 21022 is not viable for foreign-owned entities, so OSS doesn't designate a PMA issuing authority. Smaller-scale registrations (Micro / Small) for Indonesian operators are typically issued at the Regency / City level.
Beyond the NIB, KBLI 21022 carries 25 PB UMKU permits across 2 sector regulators: Pharmaceuticals (24), Veterinary & Animal Medicine (1). Most operations only need 2-4 of these — the relevant set depends on which specific activities you actually perform; Emerhub maps the right subset before filing.
KBLIs in the same subgroup 2102: 21021 (Traditional Medicine Raw Material Industry for Humans); 21023 (Traditional Medicine Product Industry for Animals); 21024 (Raw Materials Industry for Traditional Medicine (for Animals)). These are closely related activities — see the related-codes section below for full list.